Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension

Mise à jour : Il y a 4 ans
Référence : NCT00313222

Femme et Homme

Extrait

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.


Critère d'inclusion

  • Chronic Thromboembolic Pulmonary Hypertension


Liens